Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $194.19M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.43M
Average 0.36M
Big Five Numbers
Entrada Therapeutics, Inc. growth analysis
Start with the long-run numbers that show whether TRDA compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | N/A | N/A |
Revenue | N/A | N/A | N/A | -87.9% |
Equity | N/A | N/A | +2.9% | -35.6% |
Cash | N/A | N/A | +26.0% | -10.7% |
ROIC | N/A | -18.3% | -11.3% | -43.7% |
Analysis
Latest growth is strongest in Cash at -10.7% and weakest in Revenue at -87.9%. Three-year average ROIC is -11.3%, which helps show whether that growth is being earned efficiently.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +38.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +38.0% (5yr), giving you a quick read on expected growth from here.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where TRDA earns its revenue, as reported in company filings
- License
| Segment · FY2025 | Revenue | Share | YoY |
|---|---|---|---|
| License | $300K | 100.0% | -98.5% |
Figures in USD. Segments account for 1.2% of reported FY2025 revenue; $25.12M is not attributed to a segment.
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$129.6M. FCF conversion is 90.1% of net income. Operating cash flow was -$128.5M, with capex of -$1.0M. The largest bridge item is Stock-Based Comp at $19.6M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for TRDA.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for TRDA.
Competitor growth
How does Entrada Therapeutics, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Achieve Life Sciences, Inc. ACHV | $697.68M | — | — | — | —6 analysts |
Capricor Therapeutics, Inc. CAPR | $551.90M | — | — | — | —2 analysts |
Atea Pharmaceuticals, Inc. AVIR | $345.31M | — | — | — | —2 analysts |
Sagimet Biosciences Inc. SGMT | $332.99M | — | — | — | —4 analysts |
Allogene Therapeutics, Inc. ALLO | $290.58M | — | — | — | —5 analysts |
Vanda Pharmaceuticals Inc. VNDA | $241.27M | +7.0% | -2.7% | -5.3% | +17.8% (5yr)2 analysts |
Arcturus Therapeutics Holdings Inc. ARCT | $240.96M | +27.0% | +47.8% | -31.1% | +37.7% (5yr)5 analysts |
Immuneering Corporation IMRX | $240.27M | — | — | — | —5 analysts |
Humacyte, Inc. HUMA | $155.12M | — | +6.4% | +9.2% | +176.2% (5yr)2 analysts |
Voyager Therapeutics, Inc. VYGR | $107.66M | +8.8% | -25.1% | -0.4% | +15.1% (5yr)4 analysts |
Questions
Growth questions
Common questions about TRDA's growth, answered from reported and forecast figures.
Is TRDA growing revenue?
Revenue declined 87.9% year over year, from $210.78M to $25.42M.
Is TRDA turning growth into profit?
The latest net margin is -565.5%, which shows how much revenue became net income.
Continue the stock analysis
Jump to another research area for this company.